Wells Fargo
INO icon

Wells Fargo’s Inovio Pharmaceuticals INO Stock Holding History

Wells Fargo’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-83
Closed -$5K – 6584
2020
Q2 		$5K Buy
+83
New +$13.3K ﹤0.01% 5971

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's INO Position: Q1 2026 in Review

Wells Fargo increased its Inovio Pharmaceuticals (INO) stake by 4.6% in Q1 2026, buying an estimated $206 and bringing the position to 2,869 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #6120.

Wells Fargo first reported a position in INO in Q1 2014 and has held it in 49 quarters since. The position peaked at $11.1M in Q2 2020. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • Wells Fargo held 2,869 shares of Inovio Pharmaceuticals worth $4.99K as of Q1 2026.
  • Wells Fargo bought 125 Inovio Pharmaceuticals shares in Q1 2026, an estimated $206.
  • Inovio Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6120 holding.
  • Wells Fargo first reported a position in Inovio Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • Wells Fargo's Inovio Pharmaceuticals position peaked at $11.1M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.